The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 16, 2021

Filed:

Aug. 12, 2016
Applicants:

Research Institute AT Nationwide Children's Hospital, Columbus, OH (US);

University of South Florida, Tampa, FL (US);

Inventors:

Mark Edward Peeples, Bexley, OH (US);

Michael Nan-hao Teng, Tampa, FL (US);

Octavio Ramilo, Columbus, OH (US);

Maria Asuncion Mejias, Columbus, OH (US);

Emilio Flano, Needham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/155 (2006.01); C12N 7/04 (2006.01); C12N 15/00 (2006.01); C12N 15/45 (2006.01); C12N 5/10 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01); C12N 15/09 (2006.01); C07K 14/005 (2006.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); A61K 39/155 (2013.01); C07K 14/005 (2013.01); C12N 15/09 (2013.01); A61K 39/12 (2013.01); A61K 2039/5254 (2013.01); C12N 2760/18521 (2013.01); C12N 2760/18534 (2013.01); C12N 2760/18561 (2013.01);
Abstract

Embodiments disclosed herein provide compositions, methods, and uses for respiratory syncytial viruses (RSV) and immunogenic compositions thereof. Certain embodiments provide RSV having a mutated NS1 protein, where the mutation causes the uncoupling of the NS1 protein's replication and type I interferon (IFN) antagonist functions. In some embodiments, this uncoupling can produce virions capable of inducing a strong, long-lasting innate immune response while maintaining its ability to replicate in vitro. Also provided are methods for amplifying RSV in host cells, wherein amplified RSV has mutated NS1 protein in which the protein's replication and IFN antagonistic functions are uncoupled. In certain embodiments, the amplified RSV having mutated NS1 protein is formulated into immunogenic compositions, including vaccines. Other embodiments provide methods for inducing an effective immune response against RSV infection in a subject.


Find Patent Forward Citations

Loading…